Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine hydrochloride for prevention of postoperative pulmonary complications after laparoscopic radical gastrectomy
ChiCTR2500101199Phase 4Not yet recruiting
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in postoperative respiratory complications (PRC) and gastric cancer (GC) (2 arms), sponsored by General Hospital of Ningxia Medical University. Primary endpoint: Incidence of pulmonary complications within 7 days after surgery. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative respiratory complications (PRC)gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2500101199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101199.